Class-action securities suit goes forward against Amgen

A U.S. appeals court will let Amgen ($AMGN) investors keep their class-action status in a complaint accusing the company of failing to fully disclose potential safety problems with its anemia drugs Epogen and Aranesp. The shareholder that originally filed the suit also alleges Amgen promoted significant off-label use of the drugs. Report

Suggested Articles

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S. 

The agency has granted Tecentriq a priority review in previously untreated NSCLC, setting up the Roche drug for an approval decision by June 19.

Warren Buffett's Berkshire Hathaway has built a $192 million stake in Biogen, a risky investment considering aducanumab's uncertain future.